Genetic Vaccine Platforms Demonstrate Their Potential
Pharmaceutical Technology Europe
; 33(3):9-15, 2021.
Article
Dans Anglais
| ProQuest Central | ID: covidwho-20233950
ABSTRACT
Challenges with traditional vaccines The potential exists for adverse effects because live viral vaccines are attenuated by genetic mutation of the wild-type, disease-causing virus, either by passaging the virus through cells, eggs, or animals or purposeful deletion of sections of the viral genome, explains Kelly Lyn Warfield, vice president of vaccines research and development within Emergent BioSolutions' Vaccines Business Unit. "For selection and use of live, attenuated viral vaccines, caution must be applied due to potential safety issues in immunocompromised individuals (i.e., primary immunodeficiencies, patients on immunosuppressant treatment, HIV-infected people, and sometimes the very young or old), since this type of vaccine has the potential to replicate in an uncontrolled manner. spread to other individuals due to shedding of the vaccine, or revert to a virulent (disease-causing) form," she says. [...]a viral vector-based vaccine can cause an immune response to the viral vector itself in addition to the antigen of interest for which it is delivering the nucleic acid, according to Gregory Bleck, vice president of research and development at Catalent Biologies. [...]to achieve complete immune protection and to increase its duration, a prime boost dosing regimen in two consecutive vaccinations with the same or a different vaccine may be applied, which is what we're seeing in the mRNA COVID-19 vaccines," he says.
Collection:
Bases de données des oragnisations internationales
Base de données:
ProQuest Central
Les sujets:
Vaccins
langue:
Anglais
Revue:
Pharmaceutical Technology Europe
Année:
2021
Type de document:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS